Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.11

-2.6%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (593)	1/28/2000 1:02:00 PM
From: Torben Noerup Nielsen	Read Replies (1) of 52153

Peter, I'm mostly focused on the biotechs that can be expected to turn profitable by the end of this year. And for those, I simply do not see the relevance of interest rates. Take Gliatech. Barring anything really major, they'll turn profitable this year. Given their relatively low market penetration and the massive growth rate expected, it seems silly to me to consider interest rates at all. In general, I agree with your model. And the conclusion I'm coming to is that a 50 point increase by the Federal Reserve might actually be good for us as I'd expect it to actually increase the flow of money into biotech. All those funds have to have something to show by the end of the year.... Thanks, Torben

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next